Literature DB >> 25139998

Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow.

Younghun Jung1, Jingcheng Wang1, Eunsohl Lee1, Samantha McGee1, Janice E Berry1, Kenji Yumoto1, Jinlu Dai2, Evan T Keller2, Yusuke Shiozawa1, Russell S Taichman3.   

Abstract

UNLABELLED: Annexin 2 (ANXA2) plays a critical role in hematopoietic stem cell (HSC) localization to the marrow niche. In part, ANXA2 supports HSCs by serving as an anchor for stromal-derived factor-1 (CXCL12/SDF-1). Recently, it was demonstrated that prostate cancer cells, like HSCs, use ANXA2 to establish metastases in marrow. The present study determined the capacity of ANXA2 expression by bone marrow stromal cells (BMSC) to facilitate tumor recruitment and growth through ANXA2-CXCL12 interactions. Significantly more CXCL12 was expressed by BMSC(Anxa2) (+/+) than by BMSC(Anxa2) (-/-) resulting in more prostate cancer cells migrating and binding to BMSC(Anxa2) (+/+) than BMSC(Anxa2) (-/-), and these activities were reduced when CXCL12 interactions were blocked. To further confirm that BMSC signaling through ANXA2-CXCL12 plays a critical role in tumor growth, immunocompromised SCID mice were subcutaneously implanted with human prostate cancer cells mixed with BMSC(Anxa2) (+/+) or BMSC(Anxa2) (-/-). Significantly larger tumors grew in the mice when the tumors were established with BMSC(Anxa2) (+/+) compared with the tumors established with BMSC(Anxa2) (-/-). In addition, fewer prostate cancer cells underwent apoptosis when cocultured with BMSC(Anxa2) (+/+) compared with BMSC(Anxa2) (-/-), and similar results were obtained in tumors grown in vivo. Finally, significantly more vascular structures were observed in the tumors established with the BMSC(Anxa2) (+/+) compared with the tumors established with BMSC(Anxa2) (-/-). Thus, ANXA2-CXCL12 interactions play a crucial role in the recruitment, growth, and survival of prostate cancer cells in the marrow. IMPLICATIONS: The tumor microenvironment interaction between ANXA2-CXCL12 is critical for metastatic phenotypes and may impact chemotherapeutic potential. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25139998      PMCID: PMC4297714          DOI: 10.1158/1541-7786.MCR-14-0118

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

1.  Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma.

Authors:  S A Rempel; S Dudas; S Ge; J A Gutiérrez
Journal:  Clin Cancer Res       Date:  2000-01       Impact factor: 12.531

2.  Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone.

Authors:  Russell S Taichman; Carlton Cooper; Evan T Keller; Kenneth J Pienta; Norton S Taichman; Laurie K McCauley
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

3.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.

Authors:  Chris J Scotton; Julia L Wilson; Kate Scott; Gordon Stamp; George D Wilbanks; Simon Fricker; Gary Bridger; Frances R Balkwill
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

4.  Antibody-directed neutralization of annexin II (ANX II) inhibits neoangiogenesis and human breast tumor growth in a xenograft model.

Authors:  Meena Sharma; Marc R Blackman; Mahesh C Sharma
Journal:  Exp Mol Pathol       Date:  2011-10-25       Impact factor: 3.362

5.  Plasma elevation of stromal cell-derived factor-1 induces mobilization of mature and immature hematopoietic progenitor and stem cells.

Authors:  K Hattori; B Heissig; K Tashiro; T Honjo; M Tateno; J H Shieh; N R Hackett; M S Quitoriano; R G Crystal; S Rafii; M A Moore
Journal:  Blood       Date:  2001-06-01       Impact factor: 22.113

6.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

Review 7.  Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells.

Authors:  Tsvee Lapidot; Isabelle Petit
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

8.  Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors.

Authors:  Matus Studeny; Frank C Marini; Richard E Champlin; Claudia Zompetta; Isaiah J Fidler; Michael Andreeff
Journal:  Cancer Res       Date:  2002-07-01       Impact factor: 12.701

9.  G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4.

Authors:  Isabelle Petit; Martine Szyper-Kravitz; Arnon Nagler; Meir Lahav; Amnon Peled; Liliana Habler; Tanya Ponomaryov; Russell S Taichman; Fernando Arenzana-Seisdedos; Nobutaka Fujii; Judith Sandbank; Dov Zipori; Tsvee Lapidot
Journal:  Nat Immunol       Date:  2002-06-17       Impact factor: 25.606

10.  Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis.

Authors:  Younghun Jung; Jin Koo Kim; Yusuke Shiozawa; Jingcheng Wang; Anjali Mishra; Jeena Joseph; Janice E Berry; Samantha McGee; Eunsohl Lee; Hongli Sun; Jianhua Wang; Taocong Jin; Honglai Zhang; Jinlu Dai; Paul H Krebsbach; Evan T Keller; Kenneth J Pienta; Russell S Taichman
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more
  18 in total

Review 1.  The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.

Authors:  Élora Midavaine; Jérôme Côté; Philippe Sarret
Journal:  Cancer Metastasis Rev       Date:  2021-05-11       Impact factor: 9.264

Review 2.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

3.  Sympathetic Signaling Reactivates Quiescent Disseminated Prostate Cancer Cells in the Bone Marrow.

Authors:  Ann M Decker; Younghun Jung; Frank C Cackowski; Kenji Yumoto; Jingchen Wang; Russel S Taichman
Journal:  Mol Cancer Res       Date:  2017-08-16       Impact factor: 5.852

4.  Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G1 Arrest/S Phase Delay and Inhibition of Apoptosis During Chemotherapy in Bone Marrow.

Authors:  Eunsohl Lee; Ann M Decker; Frank C Cackowski; Lulia A Kana; Kenji Yumoto; Younghun Jung; Jingcheng Wang; Laura Buttitta; Todd M Morgan; Russell S Taichman
Journal:  J Cell Biochem       Date:  2016-09-26       Impact factor: 4.429

Review 5.  Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation.

Authors:  Frank C Cackowski; Russell S Taichman
Journal:  Bone       Date:  2018-02-26       Impact factor: 4.398

Review 6.  Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis.

Authors:  Sun H Park; Evan T Keller; Yusuke Shiozawa
Journal:  Calcif Tissue Int       Date:  2017-11-01       Impact factor: 4.333

Review 7.  Annexin Animal Models-From Fundamental Principles to Translational Research.

Authors:  Thomas Grewal; Carles Rentero; Carlos Enrich; Mohamed Wahba; Carsten A Raabe; Ursula Rescher
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

Review 8.  Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer.

Authors:  Clara H Lee; Ann M Decker; Frank C Cackowski; Russell S Taichman
Journal:  Cell Biol Toxicol       Date:  2019-06-27       Impact factor: 6.691

9.  Chronic myelogenous leukaemia exosomes modulate bone marrow microenvironment through activation of epidermal growth factor receptor.

Authors:  Chiara Corrado; Laura Saieva; Stefania Raimondo; Alessandra Santoro; Giacomo De Leo; Riccardo Alessandro
Journal:  J Cell Mol Med       Date:  2016-05-14       Impact factor: 5.310

10.  Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow.

Authors:  Younghun Jung; Ann M Decker; Jingcheng Wang; Eunsohl Lee; Lulia A Kana; Kenji Yumoto; Frank C Cackowski; James Rhee; Peter Carmeliet; Laura Buttitta; Todd M Morgan; Russell S Taichman
Journal:  Oncotarget       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.